Neurocrine Biosciences Stock Price Prediction
| NBIX Stock | USD 116.08 0.56 0.48% |
Oversold Vs Overbought
40
Oversold | Overbought |
Quarterly Earnings Growth (0.34) | EPS Estimate Next Quarter 1.24 | EPS Estimate Current Year 4.55 | EPS Estimate Next Year 6.82 | Wall Street Target Price 162.5 |
Using Neurocrine Biosciences hype-based prediction, you can estimate the value of Neurocrine Biosciences from the perspective of Neurocrine Biosciences response to recently generated media hype and the effects of current headlines on its competitors.
Neurocrine Biosciences Hype to Price Pattern
Investor biases related to Neurocrine Biosciences' public news can be used to forecast risks associated with an investment in Neurocrine. The trend in average sentiment can be used to explain how an investor holding Neurocrine can time the market purely based on public headlines and social activities around Neurocrine Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Neurocrine Biosciences' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Neurocrine Biosciences.
The fear of missing out, i.e., FOMO, can cause potential investors in Neurocrine Biosciences to buy its stock at a price that has no basis in reality. In that case, they are not buying Neurocrine because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Neurocrine Biosciences after-hype prediction price | USD 116.02 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Neurocrine |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurocrine Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurocrine Biosciences After-Hype Price Prediction Density Analysis
As far as predicting the price of Neurocrine Biosciences at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Neurocrine Biosciences or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Neurocrine Biosciences, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Neurocrine Biosciences Estimiated After-Hype Price Volatility
In the context of predicting Neurocrine Biosciences' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Neurocrine Biosciences' historical news coverage. Neurocrine Biosciences' after-hype downside and upside margins for the prediction period are 113.10 and 118.94, respectively. We have considered Neurocrine Biosciences' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Neurocrine Biosciences is very steady at this time. Analysis and calculation of next after-hype price of Neurocrine Biosciences is based on 3 months time horizon.
Neurocrine Biosciences Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Neurocrine Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neurocrine Biosciences backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Neurocrine Biosciences, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.30 | 2.92 | 0.06 | 0.13 | 10 Events / Month | 1 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
116.08 | 116.02 | 0.05 |
|
Neurocrine Biosciences Hype Timeline
Neurocrine Biosciences is now traded for 116.08. The entity has historical hype elasticity of -0.06, and average elasticity to hype of competition of 0.13. Neurocrine is forecasted to decline in value after the next headline, with the price expected to drop to 116.02. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.05%, whereas the daily expected return is now at -0.3%. The volatility of related hype on Neurocrine Biosciences is about 695.24%, with the expected price after the next announcement by competition of 116.21. About 97.0% of the company shares are owned by institutional investors. The book value of Neurocrine Biosciences was now reported as 24.87. The company has Price/Earnings To Growth (PEG) ratio of 0.26. Neurocrine Biosciences last dividend was issued on the 29th of December 1995. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days. Check out Neurocrine Biosciences Basic Forecasting Models to cross-verify your projections.Neurocrine Biosciences Related Hype Analysis
Having access to credible news sources related to Neurocrine Biosciences' direct competition is more important than ever and may enhance your ability to predict Neurocrine Biosciences' future price movements. Getting to know how Neurocrine Biosciences' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Neurocrine Biosciences may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| TERN | Terns Pharmaceuticals | 0.19 | 9 per month | 0.00 | (0.07) | 7.89 | (6.80) | 34.09 | |
| WVE | Wave Life Sciences | 0.65 | 9 per month | 3.01 | 0.14 | 10.01 | (5.99) | 76.01 |
Neurocrine Biosciences Additional Predictive Modules
Most predictive techniques to examine Neurocrine price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Neurocrine using various technical indicators. When you analyze Neurocrine charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Neurocrine Biosciences Predictive Indicators
The successful prediction of Neurocrine Biosciences stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Neurocrine Biosciences, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Neurocrine Biosciences based on analysis of Neurocrine Biosciences hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Neurocrine Biosciences's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Neurocrine Biosciences's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 59.73 | 85.81 | 84.97 | 89.22 | PTB Ratio | 5.86 | 6.7 | 5.77 | 6.13 |
Story Coverage note for Neurocrine Biosciences
The number of cover stories for Neurocrine Biosciences depends on current market conditions and Neurocrine Biosciences' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Neurocrine Biosciences is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Neurocrine Biosciences' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Neurocrine Biosciences Short Properties
Neurocrine Biosciences' future price predictability will typically decrease when Neurocrine Biosciences' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Neurocrine Biosciences often depends not only on the future outlook of the potential Neurocrine Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neurocrine Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 101 M | |
| Cash And Short Term Investments | 1 B |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.